Resources & Guides

Retatrutide achieved 24.2% weight loss vs semaglutide's 14.9% in trials. Compare triple-agonist vs single-agonist mechanisms, approval status, clinical data, side effects, and find out which GLP-1 medication is right for you.

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

Ozempic is FDA-approved for type 2 diabetes, Wegovy for obesity, and retatrutide is investigational. The three sit in different regulatory and clinical spaces, so the comparison has to start with what they are actually approved for.

A side-by-side look at the single, dual, and triple agonists. Trial weight loss runs 14.9% (semaglutide), 20.9% (tirzepatide), and 24.2% (retatrutide), but the trials differ and only one pairing has a head-to-head study.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

"GLP-3" is informal shorthand for triple-agonist drugs like retatrutide. This chart maps GLP-1 mono, GIP/GLP-1 dual, and triple agonists side by side on mechanism, FDA status, and trial weight loss.

A neutral look at Ro's GLP-1 program: the current branded-only medication lineup, the two-part membership and medication cost structure, and the alternatives.

Mounjaro is tirzepatide; semaglutide is Ozempic and Wegovy. Compare mechanism, SURMOUNT-5 trial data, side effects, FDA indications, and dosing side by side.

A comprehensive comparison of Shotsy alternatives for GLP-1 medication tracking. Find free tools that offer drug concentration visualization, dosing calculators, and schedule planning.

One chart, all the numbers that matter. Zepbound (tirzepatide) and Wegovy (semaglutide) compared row by row using SURMOUNT-5 head-to-head data, dosing ladders, cost, and FDA approvals.

A comprehensive comparison of GLP-1 dose calculators and plotters, examining features, drug support, and which tool best fits your medication tracking needs.

Mounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.

Zepbound and Ozempic are approved for different conditions. Zepbound targets weight management; Ozempic targets type 2 diabetes. Compare tirzepatide vs semaglutide across mechanisms, trial results, dosing, and cost.

Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) on both HbA1c reduction and weight loss in the SURPASS-2 trial. Ozempic holds the cardiovascular edge. Full comparison inside.

SURMOUNT-5 compared tirzepatide and semaglutide head-to-head for the first time. See the weight loss numbers, mechanism differences, dosing schedules, and which drug may fit your situation.

Tirzepatide achieved 20.9% weight loss vs semaglutide's 14.9% in clinical trials. The SURPASS-2 head-to-head trial showed tirzepatide superior on both A1C and weight. Compare mechanisms, side effects, dosing, costs, and which GLP-1 medication fits your situation.

Both Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.

A comprehensive comparison of Glapp alternatives for GLP-1 medication tracking. Find tools with different approaches to visualization, dosing, and educational resources.